|
WEB BASES DISCUSSION
Live
Attenuated Hepatitis A Vaccine
Recently a new live attenuated
Hepatitis A vaccine is introduced in India which was
only tried in China so far and has very limited clinical
trials. Very limited literature was found regarding it
on net. Does anybody have more information and studies
regarding it, apart from company’s monograph.
-manishagrw,
26.01.06
I have been
told that the live attenuated vaccine being promoted by
this one company is a single dose vaccine and it has
been endorsed by the IAP for vaccination against Hep A.
Further the references shown by the representative are
if no use as the seroprotection to this single dose
vaccine has been compared with seroprotection in non
immunized children and only in China. Does the IAP
actually endorse it?
-docvikas, 7.7.06
There are
lots of confusion and controversies regarding Vaccines
and vaccination schedule in our country. Every vaccine
provider practices a different schedule for vaccination.
-One
Professor at KGMU, Lucknow is advocating 2 months gap
between DPT Hib-Hep-B doses in her patients.
-Most
obstetricians give 1st dose of Hep B, on the first
postnatal visit, without caring for BCG.
-Hep-B
vaccination is the most mismanaged, with the first dose
being given from any day after birth till 2 months, and
the gap between 1st and 3rd dose may be anywhere from 3
months to an year.
-Hib vaccine
has been mentioned as optional/additional/compulsory in
different vaccination cards.
-Some are
alternately giving DPT-OPV and HepB every fortnightly.
This
prevailing confusion is because the recommendations of
IAP are not widely publicized. The least IAP could do is
to present clear guidelines as to what vaccines are
available and what is the best schedule, and publish
this in leading media channels.
-Manoj Singh,
Yamini Bal Chikitsalaya, Lucknow, 7.7.06
With so many
current and upcoming vaccines, so many different
disciplines of healthcare providers delivering them, so
many governing bodies/persons deciding need and
schedules, so many factors affecting choice-time, money,
locality, literacy status, variety of brands.
To formulate
single schedule for universal implementation is too
difficult for anybody.
Everybody has freedom to prepare and follow his own
schedule provided it conforms basics of immunization.
Tailor made
schedules with scope for circumstantial revision is need
of the time.
For guidelines answering almost all questions and
practical approach best reference is one handbook
authored by our beloved president Dr.Naveen Thacker.
-pramodmkulkarni, 7.7.06
(From
www.iapindia.org/cfforum)
Experts’ views:
The live
attenuated Hepatitis A Vaccine has been licensed for use
in China since 1992. It contains live attenuated H2
strain which was isolated from a 12 years old boy and
was attenuated by serial passage through monkey kidney
cells and human lung diploid fibroblast. The
manufacturer claims 92 to 100 percent seroconversion
with single dose administered by subcutaneous route
This vaccine
has recently been licensed for use in India. There is
only one Indian study conducted at Pune on this vaccine
showing 95% seroconversion. The vaccine has not been
studied extensively outside China. All vaccines ideally
should be subjected to post marketing surveillance for
efficacy and adverse reactions in India as being done in
the western world. As vaccine is licensed and available
it can be used, For 100% seroconversion and long term
protection second dose after 6 months should be
administered.
-Dr Shyam Kukreja,
Convener, IAP Committee On
Immunization
(In a
recently concluded CME of ID chapter of IAP at New
Delhi, the experts were of the views that the new
Chinese Hepatitis A vaccine would need more trials
before claiming it to be effective in a single dose. The
best seroconversion with the available Hepatitis-A
vaccines is achieved after 2-doses. They were quite
skeptical of the company’s claim of its efficacy in
single dose.-Editor)
Effect of Prone
and Supine Position on Sleep, Apneas, and Arousal in
Preterm Infants
OBJECTIVE.
Prematurely born compared with term born infants are at
increased risk of sudden infant death syndrome,
particularly if slept prone. The purpose of this work
was to test the hypothesis that preterm infants with or
without bronchopulmonary dysplasia being prepared for
neonatal unit discharge would sleep longer and have less
arousals and more central apneas in the prone position.
METHODS.
This was a prospective observational study in a tertiary
NICU. Twenty-four infants (14 with bronchopulmonary
dysplasia) with a median gestational age of 27 weeks
were studied at a median postconceptional age of 37
weeks. Video polysomnographic recordings of 2-channel
electroencephalogram, 2-channel electro-oculogram, nasal
airflow, chest and abdominal wall movements, limb
movements, electrocardiogram, and oxygen saturation were
made in the supine and prone positions, each position
maintained for 3 hours. The duration of sleep, sleep
efficiency (total sleep time/total recording time), and
number and type of apneas, arousals, and awakenings were
recorded.
RESULTS.
Overall, in the prone position, infants slept longer,
had greater sleep efficiency (89.5% vs 72.5%), and had
more central apneas (median: 5.6 vs 2.2), but fewer
obstructive apneas (0.5 vs 0.9). The infants had more
awakenings (9.7 vs 3.5) and arousals per hour (13.6 vs
9.0) when supine. There were similar findings in the
bronchopulmonary dysplasia infants.
CONCLUSIONS.
Very prematurely born infants studied before neonatal
unit discharge sleep more efficiently with fewer
arousals and more central apneas in the prone position,
emphasizing the importance of recommending supine
sleeping after neonatal unit discharge for prematurely
born infants. (PEDIATRICS Vol. 118 No. 1 July 2006, pp.
101-107 )
^
TOP
^
|